Aprea Therapeutics closed at $0.52 on Nov 3, up 4.89%, 63.2% below its 52-week closing high. Volume of 64.0K shares was 0.36× its 20-day average (below normal).
Split-adjusted performance: -23.8% over one month, -38.9% over six months, -63.2% over one year.
Short interest was 621.2K shares at the Oct 15 settlement, up 22.1% from the prior report (5.9% of float, 2.2 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −26.5%, revenue growth +6.4%, net margin −38.1%, P/E 16.4×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| APREAprea Therapeutics | $0.5150 | +4.89% | −38.9% | −100.0% | — | — | $6.5M | |
| XCURExicure | $1.01 | −0.98% | −70.3% | — | — | — | $6.6M | Compare |
| NAIINatural Alternatives International | $1.06 | −0.93% | −59.4% | +1.9% | −39.2% | — | $6.6M | Compare |
| CNSPCNS Pharmaceuticals | $4.55 | +3.64% | −36.4% | — | — | — | $6.6M | Compare |
| ENVBEnveric Biosciences | $1.50 | +3.45% | −56.9% | — | — | — | $6.7M | Compare |
| FBLGFibroBiologics | $0.9900 | +7.60% | −25.6% | — | — | — | $7.0M | Compare |
| ALZNAlzamend Neuro | $1.46 | +16.80% | +36.4% | — | — | — | $7.0M | Compare |
| ENSCEnsysce Biosciences | $0.3777 | −1.15% | −5.6% | −15.1% | −220.8% | — | $7.3M | Compare |
| LGVNLongeveron | $1.78 | +4.09% | −79.2% | −9.2% | −2116.0% | — | $5.7M | Compare |
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
